Actos Clinical Trials

All Categories Medications / Interventions » Aa » Actos

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Patients With Brain Tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Craniopharyngioma; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Myxopapillary Ependymoma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pilocytic Astrocytoma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Subependymal Giant Cell Astrocytoma; Adult Subependymoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Meningeal Melanocytoma; Nonmalignant Neoplasm; Recurrent Adult Brain Tumor; Tumors Metastatic to Brain
Interventions: Drug: pioglitazone hydrochloride; Other: laboratory biomarker analysis; Radiation: external beam radiation therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Pioglitazone in Patients With Mood Disorders

Conditions: Major Depressive Disorder; Insulin Resistance
Interventions: Drug: Pioglitazone; Drug: Sugar Pill
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH)
Recruiting - verified March 2012
Pioglitazone to Treat Opioid Withdrawal Symptoms

Condition: Opioid-Related Disorders
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011
Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants

Condition: Healthy
Interventions: Drug: Pioglitazone; Drug: Pioglitazone; Drug: Pioglitazone; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: MK-4074 200 mg; Drug: Placebo for MK-4074 100 mg; Drug: Pioglitazone hydrochloride 30 mg; Drug: Placebo for pioglitazone hydrochloride 30 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone

Condition: Opioid Abuse
Intervention: Drug: pioglitazone
Sponsors: Columbia University; Columbia University; Omeros Corporation
Recruiting - verified July 2011
Pioglitazone for Heroin and for Nicotine Dependence

Conditions: Heroin Dependence; Nicotine Dependence
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute on Drug Abuse (NIDA); Omeros Corporation
Recruiting - verified July 2011
Pioglitazone Hydrochloride in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: pioglitazone hydrochloride; Other: cancer prevention; Other: immunohistochemistry staining method; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified July 2011
Adipokines in Hemodialysis Patients

Conditions: End Stage Renal Disease; Hemodialysis
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: University of Utah; University of Utah; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
Recruiting - verified September 2011
Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012
Insulin Resistance in Non-alcoholic Fatty Liver Disease

Condition: Fatty Liver
Interventions: Drug: fenofibrate; Drug: pioglitazone; Drug: placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
Pioglitazone in Early Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Pioglitazone; Drug: placebo
Sponsors: University of Rochester; University of Rochester; National Institute of Neurological Disorders and Stroke (NINDS); Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified October 2011
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Pioglitazone 15 mg; Drug: Pioglitazone 45 mg; Drug: Pioglitazone 30 mg; Drug: BI 1356 / Pioglitazone 15 mg FDC; Drug: BI 1356; Drug: BI 1356 / Pioglitazone 30 mg FDC; Drug: BI 1356 / Pioglitazone 45 mg FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified April 2012
DPP-4 Inhibition and TZD for DM Prevention

Condition: Prediabetic State
Interventions: Drug: Sitagliptin + Pioglitazone PLACEBO; Drug: Sitagliptin + Pioglitazone; Drug: Sitagliptin placebo + Pioglitazone placebo
Sponsors: Emory University; Emory University
Recruiting - verified July 2011
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: placebo; Drug: pioglitazone; Dietary Supplement: Vitamin E
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified February 2012
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

Conditions: Severe, Refractory Asthma; Airway Inflammation; Airflow Obstruction
Intervention: Drug: Pioglitazone
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011
Pioglitazone for Oral Premalignant Lesions

Conditions: Malignant Neoplasm Overlapping Lip Site; Mouth Neoplasms; Malignant Neoplasm of Other and Ill-defined Sites in the Lip, Oral Cavity and Pharynx; Leukoplakia; Other Lesions of Oral Mucosa; Pigmented Oral Mucosal Lesion; Unspecified Lesions of Oral Mucosa; Oral Lichenoid Lesions; Premalignant Lesion; Other and Unspecified Lesions of Oral Mucosa; Granuloma and Granuloma-like Lesions of Oral Mucosa; Diseases of the Oral Soft Tissue, Excluding Lesions Specific for Gingiva and Tongue; Oral Premalignant Lesion; Oral Premalignant Neoplasms; Oral Leukoplakia
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Minnesota - Clinical and Translational Science Institute; Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; University of Alabama at Birmingham; University of Iowa; University of Maryland; Roswell Park Cancer Institute; Columbia University; Weill Medical College of Cornell University; European Institute of Oncology
Recruiting - verified April 2012
Pioglitazone on Pancreatic Steatosis and Bone Health

Conditions: Obesity; Type 2 Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; National Institutes of Health (NIH)
Recruiting - verified August 2011
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

Conditions: Metabolic Syndrome; Bipolar Depression; Insulin Resistance
Intervention: Drug: Pioglitazone
Sponsors: University Hospital Case Medical Center; University Hospital Case Medical Center; National Alliance for Research on Schizophrenia and Depression; Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified January 2012
Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality

Conditions: Alcoholic Chronic Pancreatitis; Insulin Resistance; Normal Stool Fat Levels; Sobriety
Intervention: Drug: Pioglitazone
Sponsors: University of Michigan; University of Michigan; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified November 2009
Pioglitazone for Lung Cancer Chemoprevention

Conditions: Lung Cancer; Endobronchial Dysplasia
Interventions: Procedure: fluorescence bronchoscopy; Procedure: quantitative high resolution CT scan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Condition: Rheumatoid Arthritis
Intervention: Drug: pioglitazone
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified October 2011
Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: pioglitazone; Drug: Placebo control
Sponsors: Stony Brook University; Stony Brook University
Recruiting - verified August 2011
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation

Conditions: Metabolic Syndrome X; Prediabetic State
Interventions: Drug: Fenofibrate; Drug: Pioglitazone and Fenofibrate; Drug: Fenofibrate; Drug: Pioglitazone and Fenofibrate
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
Insulin Resistance Intervention After Stroke Trial

Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011